RT Journal Article
SR Electronic
T1 Human Dosimetry of the <em>N</em>-Methyl-<span class="sc">d</span>-Aspartate Receptor Ligand <sup>11</sup>C-GMOM
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1330
OP 1333
DO 10.2967/jnumed.116.188250
VO 58
IS 8
A1 van der Aart, Jasper
A1 van der Doef, Thalia F.
A1 Horstman, Paul
A1 Huisman, Marc C.
A1 Schuit, Robert C.
A1 van Lingen, Arthur
A1 Windhorst, Albert D.
A1 van Berckel, Bart N.M.
A1 Lammertsma, Adriaan A.
YR 2017
UL http://jnm.snmjournals.org/content/58/8/1330.abstract
AB The methylguanidine derivative 11C-GMOM (11C-labeled N-(2-chloro-3-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine) has been used successfully to quantify N-methyl-d-aspartate (NMDA) receptor binding in humans. The purpose of the present study was to estimate the 11C-GMOM radiation dose in healthy humans. Methods: After 11C-GMOM injection, 3 female and 2 male subjects underwent 10 consecutive whole-body PET scans in approximately 77 min. Seven source organs were defined manually, scaled to a sex-specific reference, and residence times were calculated for input into OLINDA/EXM software. Accepted tissue-weighting factors were used to calculate the effective dose. Results: The mean absorbed radiation doses in source organs ranged from 7.7 μGy·MBq−1 in the brain to 12.7 μGy·MBq−1 in the spleen. The effective dose (±SD) was 4.5 ± 0.5 μSv·MBq−1. Conclusion: The effective dose of 11C-GMOM is at the lower end of the range seen for other 11C-labeled ligands, allowing for serial PET scanning in a single subject.